Standard dosing of methadone

Phase 2Small molecule

Standard dosing of methadone is one of 5 small molecule programs targeting Pain, Postoperative. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pain, PostoperativeTerminated

Pain, PostoperativePhase 2

Terminated

Competition

Competitive Landscape

9 competitors in Pain, Postoperative

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

1 2

Liposomal Bupivacaine

TTLC Biopharmaceuticals, Inc.

Phase 2

1 3

Standard Bupivacaine

TThe University of Hong Kong

Phase 2

1 4

Standard dosing of methadone

UUniversity of Florida

Phase 2

1 5

Bupivacaine Hydrochloride

NNorthwestern University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pain, Postoperative1 trial

Dosing of Methadone for Spine Surgery

Terminated·UUniversity of Florida·Phase 2·NCT03605901·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Standard dosing of methadone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard dosing of methadone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard dosing of methadone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Florida

Standard dosing of methadone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pain, Postoperative1 trial

References

Drug Info

Quick Facts

Related News